Shukai Xia

This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Biosion, Inc.. Active years: 2023-2026.

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 2.6

ph-index = 1

Company Filing History:

7 out of 11

Biosion, Inc.

patents

Years Active: 2023-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735495 - ANTIBODIES BINDING IL4R AND USES THEREOF (2026-09-15),

2. 12723082 - MONOCLONAL ANTIBODIES WHICH BIND PD-1, ENCODING NUCLEOTIDES THEREOF AND METHOD OF USE THEREOF TO TREAT CANCER, INFECTIOUS DISEASE AND INFLAMMATORY DISEASE (2026-09-01),

3. 12703763 - ANTIBODIES BINDING C5 AND USES THEREOF (2026-08-11),

4. 12679900 - ANTIBODIES BINDING RANKL AND USES THEREOF (2026-07-14),

5. 12649789 - ANTIBODIES BINDING SIGLEC15 AND USES THEREOF (2026-06-09),

6. 12559565 - ANTIBODIES BINDING CTLA4 AND USES THEREOF (2026-02-24),

7. 11739147 - Antibodies binding Siglec15 and uses thereof (2023-08-29),

Title: Shukai Xia - Innovator in Antibody Development

Introduction

Shukai Xia is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions for medical treatments, showcasing his expertise and dedication to advancing healthcare.

Latest Patents

Shukai Xia holds a patent for "Antibodies binding Siglec15 and uses thereof." This patent describes an isolated monoclonal antibody that specifically binds to human Siglec15, or an antigen-binding portion thereof. The patent also includes a nucleic acid molecule encoding the antibody, an expression vector, a host cell, and a method for expressing the antibody or its antigen-binding portion. Furthermore, the disclosure provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus, and a pharmaceutical composition that incorporates the antibody or its antigen-binding portion, along with a treatment method utilizing these innovations. He has 1 patent to his name.

Career Highlights

Shukai Xia is currently associated with Biosion, Inc., where he continues to push the boundaries of antibody research and development. His work at the company emphasizes the importance of innovative therapeutic solutions in the medical field.

Collaborations

Shukai Xia collaborates with various professionals in the industry, including his coworker Mingjiu Chen. These collaborations enhance the research and development efforts at Biosion, Inc., fostering a dynamic environment for innovation.

Conclusion

Shukai Xia is a notable inventor whose work in antibody development is paving the way for new medical treatments. His contributions to biotechnology reflect a commitment to improving healthcare through innovation.